To include your compound in the COVID-19 Resource Center, submit it here.

Panel recommends against Xarelto for ACS

FDA's Cardiovascular and Renal Drugs Advisory Committee voted 6-4, with one abstention, against recommending approval of 2.5 mg twice-daily Xarelto

Read the full 204 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE